Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.
21 Jun 2017

Menarini Ricerche to present the most recent data about the pre-clinical development of its novel ADC MEN1309/OBT076 at the 29th Pezcoller Symposium

Pomezia, June 21, 2017Menarini Ricerche and the UK company Oxford BioTherapeutics (OBT) will present the latest data about their novel antibody drug-conjugate (ADC) MEN1309/OBT076, in development for solid and haematological tumors, at the 29th Pezcoller Symposium which will take place on June 22,23 2017 in Trento, Italy.

Results of the preclinical studies of the novel ADC, as well as the characterization of its target antigen Ly75/CD205, will be summarized in a poster entitled: “MEN1309/OBT076: a novel Antibody-Drug Conjugate targeting the Ly75/CD205 antigen”.

The poster will focus on the antitumor activity of MEN1309/OBT076 in vitro and in vivo. Indeed, MEN1309/OBT076 showed impressive anti-tumoral activity against NHL and triple negative breast cancer cell lines, in the corresponding xenograft models and in Patient-Derived Xenograft (PDX) models.


About MEN1309/OBT076

MEN1309/OBT076 is a fully humanized IgG1 monoclonal antibody conjugated to a potent cytotoxic maytansinoid toxin via a cleavable linker. The ADC is directed against a type I transmembrane glycoprotein and a C-type lectin receptor Ly75/ CD205, that is over-expressed in several solid tumors and non-Hodgking lymphomas (NHL). 


Concession granted by Italian Ministry for Cultural Heritage and Activities Read more